$AWH
Aspira Women's Health Inc.

2023 Q3 Form 10-Q Financial Statement

#000092661723000070 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $2.217M $2.491M
YoY Change 7.0% 20.57%
Cost Of Revenue $910.0K $941.0K
YoY Change -0.66% -14.45%
Gross Profit $1.307M $1.550M
YoY Change 13.06% 60.46%
Gross Profit Margin 58.95% 62.22%
Selling, General & Admin $4.425M $5.178M
YoY Change -49.11% -33.41%
% of Gross Profit 338.56% 334.06%
Research & Development $998.0K $693.0K
YoY Change -53.73% -50.85%
% of Gross Profit 76.36% 44.71%
Depreciation & Amortization $40.00K $52.00K
YoY Change -40.3% -18.75%
% of Gross Profit 3.06% 3.35%
Operating Expenses $5.423M $5.871M
YoY Change -50.03% -36.09%
Operating Profit -$4.116M -$4.321M
YoY Change -57.55% -47.43%
Interest Expense $10.00K $8.000K
YoY Change -99.8% -180.0%
% of Operating Profit
Other Income/Expense, Net $599.0K $1.004M
YoY Change 411.97% -7823.08%
Pretax Income -$4.710M -$2.317M
YoY Change 3.33% -71.89%
Income Tax
% Of Pretax Income
Net Earnings -$4.706M -$2.317M
YoY Change 3.25% -71.89%
Net Earnings / Revenue -212.27% -93.01%
Basic Earnings Per Share -$0.48 -$0.28
Diluted Earnings Per Share -$0.48 -$0.28
COMMON SHARES
Basic Shares Outstanding 10.20M 8.391M
Diluted Shares Outstanding 9.776M 8.400M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.100M $4.246M
YoY Change -75.18% -79.27%
Cash & Equivalents $5.100M $4.246M
Short-Term Investments
Other Short-Term Assets $600.0K $706.0K
YoY Change -36.44% -39.81%
Inventory $301.0K $272.0K
Prepaid Expenses
Receivables $1.590M $1.638M
Other Receivables $0.00 $0.00
Total Short-Term Assets $7.572M $6.862M
YoY Change -67.04% -70.11%
LONG-TERM ASSETS
Property, Plant & Equipment $221.0K $261.0K
YoY Change -47.0% -40.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.00K $255.0K
YoY Change -94.8% 347.37%
Total Long-Term Assets $1.090M $858.0K
YoY Change 12.84% -19.06%
TOTAL ASSETS
Total Short-Term Assets $7.572M $6.862M
Total Long-Term Assets $1.090M $858.0K
Total Assets $8.662M $7.720M
YoY Change -63.82% -67.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.382M $1.072M
YoY Change -26.99% -21.98%
Accrued Expenses $3.089M $3.549M
YoY Change -38.07% -29.85%
Deferred Revenue
YoY Change
Short-Term Debt $77.00K $306.0K
YoY Change 17.69%
Long-Term Debt Due $378.0K $259.0K
YoY Change 10.2% -8.48%
Total Short-Term Liabilities $5.162M $5.374M
YoY Change -29.26% -23.71%
LONG-TERM LIABILITIES
Long-Term Debt $1.217M $1.334M
YoY Change -49.84% -47.4%
Other Long-Term Liabilities $2.900M $1.540M
YoY Change -4.64% 390.45%
Total Long-Term Liabilities $1.217M $1.334M
YoY Change -49.84% -47.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.162M $5.374M
Total Long-Term Liabilities $1.217M $1.334M
Total Liabilities $9.321M $8.248M
YoY Change -26.97% -16.64%
SHAREHOLDERS EQUITY
Retained Earnings -$515.2M -$507.3M
YoY Change 4.34% 3.69%
Common Stock $11.00K $9.000K
YoY Change -91.13% -91.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$659.0K -$528.0K
YoY Change
Total Liabilities & Shareholders Equity $8.662M $7.720M
YoY Change -63.82% -67.85%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$4.706M -$2.317M
YoY Change 3.25% -71.89%
Depreciation, Depletion And Amortization $40.00K $52.00K
YoY Change -40.3% -18.75%
Cash From Operating Activities $3.321M $3.417M
YoY Change -138.47% -154.2%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $4.000K
YoY Change -100.0% -117.39%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$4.000K
YoY Change -100.0% -82.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.180M 134.0K
YoY Change -52.26% -379.17%
NET CHANGE
Cash From Operating Activities 3.321M 3.417M
Cash From Investing Activities 0.000 -4.000K
Cash From Financing Activities 4.180M 134.0K
Net Change In Cash 3.321M 3.417M
YoY Change 4577.46% -153.6%
FREE CASH FLOW
Cash From Operating Activities $3.321M $3.417M
Capital Expenditures $0.00 $4.000K
Free Cash Flow $3.321M $3.413M
YoY Change -138.71% -154.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Central Index Key
EntityCentralIndexKey
0000926617
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34810
dei Entity Registrant Name
EntityRegistrantName
Aspira Women’s Health Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Building III
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
519-0400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AWH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10198341
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4246000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13306000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
57000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
706000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
9000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1638000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1245000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
506745000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
505621000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-507282000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1442000
CY2023Q2 us-gaap Inventory Net
InventoryNet
272000
CY2022Q4 us-gaap Inventory Net
InventoryNet
316000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
6862000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16309000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
261000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
342000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
282000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
255000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
251000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
163000
CY2023Q2 us-gaap Assets
Assets
7720000
CY2022Q4 us-gaap Assets
Assets
17373000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
881000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3549000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3650000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
259000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
306000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
764000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
188000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5374000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5775000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1334000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
228000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1312000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2280000
CY2023Q2 us-gaap Liabilities
Liabilities
8248000
CY2022Q4 us-gaap Liabilities
Liabilities
10642000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8473363
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8473363
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8306326
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8306326
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498898000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-528000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6731000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7720000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17373000
CY2023Q2 us-gaap Revenues
Revenues
2491000
CY2022Q2 us-gaap Revenues
Revenues
2066000
us-gaap Revenues
Revenues
4807000
us-gaap Revenues
Revenues
3959000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
941000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1100000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2066000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2032000
CY2023Q2 us-gaap Gross Profit
GrossProfit
1550000
CY2022Q2 us-gaap Gross Profit
GrossProfit
966000
us-gaap Gross Profit
GrossProfit
2741000
us-gaap Gross Profit
GrossProfit
1927000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
693000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1410000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1924000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2758000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1772000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3580000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4334000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8077000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3406000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4196000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6573000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8559000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5871000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9186000
us-gaap Operating Expenses
OperatingExpenses
12831000
us-gaap Operating Expenses
OperatingExpenses
19394000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4321000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8220000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10090000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17467000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-992000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-968000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
34000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-28000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1004000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
704000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2317000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8243000
us-gaap Net Income Loss
NetIncomeLoss
-8384000
us-gaap Net Income Loss
NetIncomeLoss
-17511000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.34
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8400157
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8400157
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7482860
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7482860
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8357013
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8357013
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7479435
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7479435
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6731000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6067000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
133000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
827000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2317000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47000
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
169000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
264000
CY2023Q2 awh Common Stock Value Issued For Entering Into Equity Line Of Credit
CommonStockValueIssuedForEnteringIntoEquityLineOfCredit
258000
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
224000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-528000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9268000
CY2022Q1 awh Common Stock Issued In Conjunction With Exercise Of Stock Options
CommonStockIssuedInConjunctionWithExerciseOfStockOptions
2000
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
838000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8243000
CY2022Q2 awh Common Stock Issued In Conjunction With Exercise Of Stock Options
CommonStockIssuedInConjunctionWithExerciseOfStockOptions
11000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
140000
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
470000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14122000
us-gaap Net Income Loss
NetIncomeLoss
-8384000
us-gaap Net Income Loss
NetIncomeLoss
-17511000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
7000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
122000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
128000
us-gaap Share Based Compensation
ShareBasedCompensation
621000
us-gaap Share Based Compensation
ShareBasedCompensation
1448000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-968000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
258000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
393000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
85000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-899000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-408000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-44000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-326000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-855000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9123000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16477000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
105000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
167000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
131000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
211000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
134000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
169000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
79000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-118000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9056000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16700000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13557000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37430000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4501000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20730000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4246000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20480000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
255000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4501000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20730000
us-gaap Interest Paid Net
InterestPaidNet
33000
us-gaap Interest Paid Net
InterestPaidNet
38000
us-gaap Line Of Credit Facility Decrease Forgiveness1
LineOfCreditFacilityDecreaseForgiveness1
1000000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
258000
us-gaap Nature Of Operations
NatureOfOperations
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Organization </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 6pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Aspira Women’s Health Inc., (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company</span><span id="BKMK_206" style="text-decoration: none;"></span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">”) is incorporated in the state of Delaware, and is engaged in the business of discovering, developing and commercializing risk assessment and diagnostic tests for gynecologic disease. The Company currently markets and distributes the following products and related services: (1) Ova1Plus, a non-invasive blood test that combines two FDA-cleared tests for women with pelvic masses who are planned for surgery: Ova1, leveraging its high sensitivity, and Overa, with its high specificity; and (2) OvaWatch, a non-invasive blood test used to assess the risk of ovarian cancer for women with adnexal masses, evaluated by initial clinical assessment as likely benign or indeterminant with a negative predictive value of 99%.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0.06in;margin-top: 0;text-indent: 0.50in;"><span style="white-space:pre-wrap; background: #FFFFFF;color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Collectively, these tests are referred to and marketed as OvaSuite.</span><span style="white-space:pre-wrap; font-family: 'Segoe UI', 'sans-serif';font-size: 9pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Revenue from these sources is included in total revenue in the results of operations for the three and six months ended June 30, 2023 and 2022, respectively.</span></p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4246000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
255000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-507282000
CY2023Q2 awh Working Capital
WorkingCapital
1488000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2317000
us-gaap Net Income Loss
NetIncomeLoss
-8384000
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3417000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9123000
CY2023Q3 awh Market Capitalisation
MarketCapitalisation
35000000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
awh Adjustments To Estimates Of Variable Consideration To Derecognize Revenue
AdjustmentsToEstimatesOfVariableConsiderationToDerecognizeRevenue
0
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
96000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
110000
CY2022Q2 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2022Q2 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023Q2 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023Q2 us-gaap Financing Receivable Collectively Evaluated For Impairment
FinancingReceivableCollectivelyEvaluatedForImpairment
0
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
308000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
767000
CY2023Q2 awh Prepaid Software Licenses
PrepaidSoftwareLicenses
157000
CY2022Q4 awh Prepaid Software Licenses
PrepaidSoftwareLicenses
269000
CY2023Q2 awh Prepaid Subscriptions
PrepaidSubscriptions
32000
CY2022Q4 awh Prepaid Subscriptions
PrepaidSubscriptions
211000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
209000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
195000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
706000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1442000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1000000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
1593000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
2718000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
259000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
403000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1334000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2315000
CY2023Q2 us-gaap Contractual Obligation
ContractualObligation
1603000
CY2023Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
26000
CY2023Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
475000
CY2023Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
485000
CY2023Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
477000
CY2023Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
140000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
112000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
164000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
124000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
64000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
464000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
48000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
416000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
57000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
51000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0871
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0932
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1430000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2051000
CY2023Q2 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
207000
CY2022Q4 awh Collaboration And Research Agreement Costs
CollaborationAndResearchAgreementCosts
404000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1198000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
556000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
714000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
639000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3549000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3650000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 awh Stock Issuance Expenses
StockIssuanceExpenses
11000
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
13.20
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
144545
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2317000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8243000
us-gaap Net Income Loss
NetIncomeLoss
-8384000
us-gaap Net Income Loss
NetIncomeLoss
-17511000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8400157
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8400157
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7482860
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7482860
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8357013
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8357013
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7479435
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7479435
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.34

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000926617-23-000070-index-headers.html Edgar Link pending
0000926617-23-000070-index.html Edgar Link pending
0000926617-23-000070.txt Edgar Link pending
0000926617-23-000070-xbrl.zip Edgar Link pending
awh-20230630.xsd Edgar Link pending
awh-20230630x10q.htm Edgar Link pending
awh-20230630xex31_1.htm Edgar Link pending
awh-20230630xex31_2.htm Edgar Link pending
awh-20230630xex32_1.htm Edgar Link pending
awh-20230630_lab.xml Edgar Link unprocessable
awh-20230630_def.xml Edgar Link unprocessable
awh-20230630_cal.xml Edgar Link unprocessable
awh-20230630_pre.xml Edgar Link unprocessable
awh-20230630x10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending